New combo therapy shows promise for tough bladder cancer
NCT ID NCT03575013
First seen Jan 07, 2026 · Last updated May 23, 2026 · Updated 21 times
Summary
This early-stage study tested a combination of two drugs—avelumab (an immunotherapy) and docetaxel (a chemotherapy)—in 21 people with advanced bladder cancer that had stopped responding to standard platinum chemotherapy. The goal was to see if the combination was safe and could shrink tumors. While not a cure, the approach aims to give patients more treatment options when others have failed.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.